Articles

AMYRT

Investorideas.com - Coverage Initiated on Biotech; Analyst Says, 'Time to Buy'

ADAP

ALEXION

A SUVRE

Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) | Business Wire

CAC40...a suivre

ORAPI : Résultats annuels 2017 - premiers signaux positifs : ROC 26,1%

BOIRON

TOYS '' RUS''

VOLKSWAGEN